Vaccine against african swine fever virus infection
AssigneesThe Pirbright Institute, Kumamoto University, The Chancellor, Masters and Scholars of the University of Oxford
InventorsLinda Dixon, Ana Reis, Anusyah Rathakrishnan, Simon Davis, Yuan Jenq Lui, Shinji Ikemizu
Life of this patent
Estimating the term…
Abstract
The present invention relates to attenuated African Swine Fever viruses. The attenuated viruses protect pigs against subsequent challenge with virulent virus. The present invention also relates to the use of such attenuated viruses to treat and/or prevent African Swine Fever. The invention also relates to EP402R proteins of African Swine Fever virus comprising particular amino acid substitutions, as well as polynucleotides encoding such proteins and African Swine Fever viruses comprising such proteins.
Claims82
An attenuated African Swine Fever (ASF) virus in which the expression and/or activity of the genes EP153R and EP402R is disrupted;
- and which comprises a functional version of one or more of the following genes:
- multigene family (MGF) 110 3L, 6L, 7L, 8L, 10L, 11L and 12L,
- MGF 360 5L, 6L, 7L, 10L, 11L, 12L, 13L, 14L, 20R, 21R and 22R, and
- MGF 505 1R, 2R and 6R.
An attenuated ASF virus in which the expression and/or activity of the genes EP153R and EP402R is disrupted and which comprises a DIVA mutation.
An EP402R protein comprising one or more amino acid change in the ligand-binding domain wherein the amino acid change disrupts ligand-binding of the EP402R protein.
An EP402R protein comprising one or more amino acid change at a position which corresponds to Q96 and/or W99 of the Georgia 2007/1 EP402R protein (SEQ ID No. 24).
A method of reducing the ability of an ASF virus to induce haemadsorption, the method comprising changing one or more amino acid changes in the ligand-binding domain of the EP402R protein wherein the amino acid changes disrupt ligand-binding of the EP402R protein.
A method of reducing the ability of an ASF virus to induce haemadsorption, the method comprising changing an amino acid in the EP402R protein at a position which corresponds to Q96 and/or W99 of the Georgia 2007/1 EP402R protein (SEQ ID No. 24).
A method of attenuating an ASF virus which comprises disrupting the expression and/or activity of the EP153R and EP402R genes.
Dependencies are inferred from the claim text.